Press Room

2007 Press Releases

TSX:V - IXS
NASD OTC:BB: IXSBF

June 20, 2007

InNexus Named to TSX Venture Top 50

British COLUMBIA, Canada -- InNexus Biotechnology Inc. (TSX VENTURE: IXS) (OTCBB: IXSBF), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, is pleased to announce that it has been selected as one of the 2007 TSX Venture 50, a ranking of the top 10 public venture capital companies in five industry sectors listed on the TSX Venture Exchange. Jeff Morhet, President and CEO of InNexus, stated, “There are over 2000 companies listed on the TSX Venture Exchange and we are honored to be among the top 50. As an early stage Canadian-based biotech also operating in the U.S., we are pleased that our technology, strategy and accomplishments are being recognized by the TSXV. We look forward to building InNexus into a world class developer of medicines to treat cancer and other hard-to-treat diseases and we appreciate our shareholders for recognizing our focus and commitment.”

The criteria to determine the TSX Venture 50 is based on a formula consisting of revenue, return on investment, market capitalization growth and trading volume for the top 10 companies in each of five industry sectors - life sciences, mining, oil & gas, technology and diversified industries - with the initial selection data being compiled as at December 31, 2006. The 2007 TSX Venture 50 will be published in the Globe and Mail newspaper on June 20, 2007 across Canada.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of The Mayo Clinic and has its own in–house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

Contact:

Jeff Morhet
President & Chief Executive Officer
InNexus Biotechnology Inc.
jmorhet@ixsbio.com
480-862-7500